Skyhawk Therapeutics

Skyhawk Therapeutics is pleased to be presenting at the upcoming EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium highlighting preclinical data on SKY-1214, the company’s investigational, oral FANCL/FANCI targeting RNA splicing modulator being developed for difficult to treat multiple myeloma and non-Hodgkin’s lymphoma. Read the full release here: https://lnkd.in/eHhSV9sh #MultipleMyeloma #EORTC #NCI #AACR #RareDisease #SkyhawkTx #DrugDevelopment #SmallMoleculeRNA #RNA #BloodCancer

Skyhawk Therapeutics is pleased to present additional topline data from Parts A and B of its Phase 1 clinical trial of SKY-0515 at the European Huntington’s Disease Network and Enroll-HD 2024 meeting in Strasbourg, France. Skyhawk is currently enrolling Huntington’s patients in Part C of its Phase 1 clinical trial and is on track to report topline data from the trial in Q2 2025. Learn More: https://lnkd.in/eJ2Jpf4V #HuntingtonsDisease #EHDN #RareDisease #SkyhawkTx #DrugDevelopment #SmallMoleculeRNA #RNA

Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction The Skyhawk team is delighted with the speed at which this study was conducted and thrilled to report such compelling results for SKY-0515. These topline data represent a crucial step forward for SKY-0515 and demonstrate the immense potential of the Skyhawk platform to target indications for which there are no approved disease modifying therapies. Learn More: https://lnkd.in/eYBJAnUH #HuntingtonsDisease #DrugDevelopment #Skyhawk #SmallMoleculeRNA 

Skyhawk Therapeutics is pleased to announce the recent promotion of Clint Musil from Chief Financial Officer to Chief Executive Officer and the appointment of Bill Haney as Executive Chairman of the Board of Directors, effective February 2024. “Clint is an exceptional leader with considerable public biopharma company experience. With Skyhawk’s first program for Huntington’s disease progressing in the clinic and our second program on track to enter the clinic, Clint’s talent, energy and focus are ideally suited to drive Skyhawk as we work towards continued growth.” – Bill Haney, Executive Chairman of the Board of Directors. Learn More: https://lnkd.in/eY25eNqp

The Skyhawk Therapeutics team is excited to be on the ground in New York City for the Jefferies Healthcare Conference! #RNA #DrugDevelopment #SmallMoleculeRNA #SkyhawkTx #Jefferies24

The Skyhawk Therapeutics team is excited to connect with other biotech pioneers this week at the BIO International Conference in San Diego from June 3-6! #RNA #DrugDevelopment #SmallMoleculeRNA #SkyhawkTx #BIO24

SKY-0515 is a small molecule RNA splicing modifier developed through our novel SKYSTAR® platform. Having successfully advanced through single asending dose, SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study for Huntington's Disease https://lnkd.in/g8JKgDh7

Our Waltham/HQ Team has moved! Ribbon Cutting Ceremony and Celebration in our beautiful new facility.